Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer

Advances in Therapy

Volumn 25, Issue 8, 2008, Pages 801-809

  Yamac, Deniz ^a   Ozturk, Banu ^a   Coskun, Ugur ^a   Tekin, Ercument ^a   Sancak, Banu ^a   Yildiz, Ramazan ^a   Atalay, Can ^b  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b ANKARA ONCOLOGY HOSPITAL   (Turkey)

Author keywords

Breast cancer; Locally advanced; Prognosis; YKL 40

Indexed keywords

CHI3L1 PROTEIN, HUMAN; GLYCOPROTEIN; GROWTH PROMOTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MORTALITY; PROGNOSIS; SURVIVAL RATE;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GLYCOPROTEINS; GROWTH SUBSTANCES; HUMANS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 58749083936     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-008-0082-2     Document Type: Article

References (24)

1. Johansen JS, Williamson MK, Rice RS, Price PA. Identifcation of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res. 1992;7:501-512.
2. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers. 2006;15:194-202. (Pubitemid 43342164)
3. Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem. 1993;268:25803-25810. (Pubitemid 23358198)
4. Johansen JS, Christensen IJ, Riisbro R, et al. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Breast Cancer Res Tr eat. 2003;80:15-21. (Pubitemid 36851281)
5. Johansen JS, Cintin C, Jørgensen M, Kamby C, Price PA. Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer. Eur J Cancer. 1995;31A:1437-1442.
6. Cintin C, Johansen JS, Christensen IJ, Price PA, Sørensen S, Nielsen HJ. High serum YKL-40 level afer surgery for colorectal carcinoma is related to short survival. Cancer. 2002;95:267-274. (Pubitemid 34787591)
7. Johansen JS, Drivsholm L, Prica PA, Christensen IJ. High serum YKL-40 levels in patients with small cell lung cancer is related to early death. Lung Cancer. 2004;46:333-340. (Pubitemid 39487308)
8. Huang Y, Prasad M, Lenon WJ, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profles. Proc Natl Acad Sci USA. 2001;98:15044-15049. (Pubitemid 34013966)
9. Dupont J, Tanwar MK, Taler HT, et al. Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol. 2004;22:3330-3339. (Pubitemid 41103690)
10. Brasso K, Christensen IJ, Johansen JS, et al. Prognostic value of PINP, bone alkaline phosphatase, CTX-1, and YKL-40 in patients with metastatic prostate carcinoma. Prostate. 2006;66:503-513.
11. Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res. 2002;62:4364-4368. (Pubitemid 34827294)
12. Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, Maase H. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer. 2006;106:1130-1139.
13. Rehli M, Krause SW, Andressen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3LI), a member of the chitinase protein family and marker for late stages of macrophage diferentiation. Genomics. 1997;43:221-225. (Pubitemid 27335226)
14. Rehli M, Niller H-H, Ammon C, et al. Transcriptional regulation of CHI3LI, a marker gene for late stages of macrophage diferentiation. J Biol Chem. 2003;278:44058-44067. (Pubitemid 37377146)
15. Stokes DG, Liu G, Coimbra IB, Piera-Velazquez S, Crowl RM, Jimenez SA. Assessment of the gene expression profle of diferentiated and dediferentiated human fetal chondrocytes by microarray analysis. Arthritis Rheum. 2002;46:404-419. (Pubitemid 34136578)
16. Imabayashi H, Mori T, Gojo S, et al. Rediferentiation of dediferentiated chondrocytes and chondrogenesis of human bone marrow stromal cells via chondrosphere formation with expression profling by large-scale cDNA analysis. Exp Cell Res. 2003;288:35-50. (Pubitemid 36870996)
17. De Ceuninck F, Gaufllier S, Bonnaud A, Sabatini M, Lesur C, Pastoureau P. YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synocytes and increases glycoaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun. 2001;285:926-931. (Pubitemid 32918025)
18. Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage 39 (HC-gp39) stimulates proliferation of human connective tissue cells and activates both extracellular signal-regulated kinase-and protein kinase B-mediated signalling pathways. Biochem J. 2002;365:119-126. (Pubitemid 34756146)
19. Ling H, Reclies AD. The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the infammatory cytokines interleukin-1 and tumor necrosis factor-α. Biochem J. 2004;380:651-659. (Pubitemid 38850506)
20. Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Milis AJT. Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res. 1999;250:168-173. (Pubitemid 29391580)
21. Nishikawa KC, Milis AJT. Gp38k (CHI3LI) is a novel adhesion and migration factor for vascular cells. Exp Cell Res. 2003;287:79-87. (Pubitemid 36683203)
22. Jensen BV, Johansen JS, Price PA. High levels of serum Her-2/neu and YKL-40 independently rEffect aggressiveness of metastatic breast cancer. Clin Cancer Res. 2003;9:501-512.
23. Cintin C, Johansen JS, Christensen IJ, Price PA, Serensen S, Nielsen HJ. Serum YKL-40 and colorectal cancer. Br J Cancer. 1999;79:1494-1499. (Pubitemid 29116810)
24. Dehn H, Hodall EVS, Johansen JS, et al. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. Acta Obstet Gynecol Scand. 2003;82:287-293. (Pubitemid 36459738)